Iron deficiency and anaemia in heart failure: understanding the FAIR‐HF trial

González-Costello, José; Comín‐Colet, Josep

doi:10.1093/eurjhf/hfq165

Cited by 43 publications

(31 citation statements)

References 28 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the criteria most-commonly used for detecting this condition are a ferritin level <100 μg/l, or a ferritin level 100-300 μg/l in combination with transferrin saturation <20%. [32][33][34] Using these criteria, a large study published in 2010 showed that iron deficiency was present in 37% of all patients with HF. 35 Interestingly, in this study, iron deficiency was detected in one-third of patients with normal hemoglobin levels.…”

Section: Introductionmentioning

confidence: 99%

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Veldhuisen

Anker

Ponikowski³

et al. 2011

Nat Rev Cardiol

182

142

View full text Add to dashboard Cite

Anemia and iron deficiency are common in patients with heart failure (HF), and are associated with worse symptoms and adverse outcomes in this population. Although the two can occur together, anemia in HF is often not caused by iron deficiency, and iron deficiency can be present without causing anemia. Erythropoiesis-stimulating agents have been investigated extensively in the past few years and might be of benefit in patients with HF and anemia. However, concerns have arisen regarding the safety of erythropoiesis-stimulating agents in patients with chronic kidney disease and so the results of a large mortality trial are eagerly awaited to provide information on safety in patients with HF. Iron supplementation or replacement is a much older treatment option for patients with HF and anemia, but questions about the safety of intravenous iron, and absorption problems with oral formulations have prevented its widespread use to date. In the past few years, however, new data on the importance of iron deficiency in HF have become available, and a number of studies with intravenous iron have shown promising results. Therefore, this treatment approach is likely to become an attractive option for patients with HF and iron deficiency, both with and without anemia.

show abstract

Section: Introductionmentioning

confidence: 99%

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Veldhuisen

Anker

Ponikowski³

et al. 2011

Nat Rev Cardiol

182

142

View full text Add to dashboard Cite

show abstract

“…It has been postulated that oral iron may not be effective in patients with chronic HF owing to potentially impaired absorption and delivery. 11 oral iron, 12 trials exploring the utility of oral iron supplementation in HF have not been performed. Therefore, the present retrospective study was conducted to investigate the efficacy of oral iron supplements in improving iron stores in patients with HFrEF and iron deficiency.…”

mentioning

confidence: 99%

Repletion of Iron Stores With the Use of Oral Iron Supplementation in Patients With Systolic Heart Failure

Niehaus

Malhotra

Cocca-Spofford

et al. 2015

Journal of Cardiac Failure

View full text Add to dashboard Cite

“…Hematinic deficiencies have been described in 53% of outpatients with anemia and CHF, and in another study, 57% of 148 patients had coexisting CHF and anemia due to reduced EPO levels and/or reduced iron levels [127]. Iron deficiency (ferritin <100 lg/L or ferritin 100-299 lg/L with transferrin saturation <20%) was present in 50% of an international pooled cohort of 1506 CHF patients.…”

Section: Anemiamentioning

confidence: 94%

Management of Noncardiac Comorbidities in Chronic Heart Failure

Chong

Singh

Parry

et al. 2015

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SummaryPrevalence of heart failure is increasing, especially in the elderly population. Noncardiac comorbidities complicate heart failure care and are increasingly common in elderly patients with reduced or preserved ejection fraction heart failure, owing to prolongation of patient's lives by advances in chronic heart failure (CHF) management. Common comorbidities include respiratory disease, renal dysfunction, anemia, arthritis, obesity, diabetes mellitus, cognitive dysfunction, and depression. These conditions contribute to the progression of the disease and may alter the response to treatment, partly as polypharmacy is inevitable in these patients. Cardiologists and other physicians caring for patients with CHF need to be vigilant to comorbid conditions that complicate the care of these patients. There is now more guidance on management of noncardiac comorbidities in heart failure, and this article contains a comprehensive review of the most recent updates on management of noncardiac comorbidities in CHF.

show abstract

Iron deficiency and anaemia in heart failure: understanding the FAIR‐HF trial

Cited by 43 publications

References 28 publications

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Repletion of Iron Stores With the Use of Oral Iron Supplementation in Patients With Systolic Heart Failure

Management of Noncardiac Comorbidities in Chronic Heart Failure

Contact Info

Product

Resources

About